Furosemide-Induced Ototoxicity

Brief Reports1 November 1979Furosemide-Induced OtotoxicityKEVIN L. GALLAGHER, R.PH., JUDITH K. JONES, M.D., Ph.D.KEVIN L. GALLAGHER, R.PH., JUDITH K. JONES, M.D., Ph.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-91-5-744 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe Adverse Drug Reaction Reporting Program of the Division of Drug Experience, Food and Drug Administration (1), has received 29 case reports of deafness associated with the administration of furosemide out of 878 total reports of experiences with this drug. Although deafness is known to result when furosemide is administered in high doses or to patients with renal failure, some of these cases suggest the need for greater awareness of this potential effect, particularly since this is one of the five most frequently prescribed drugs in the United States (2). The patients affected (summarized in Table 1) ranged from 20...References1. Division of Drug Experience (HFD-210), Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20857. Google Scholar2. 1978: top 200 drugs. Pharm Times. 1979; April: 29-36. MedlineGoogle Scholar3. DAVIES D. Drug-induced deafness. Adverse Drug React Bull. 1978;69:244-77. CrossrefGoogle Scholar4. DARGIEDOLLEY HC. Adverse reactions to diuretic drugs. In: DUKES MNG, ed. Meyler's Side Effects of Drugs, vol. 8. New York: Elsevier-North Holland Publishing Co.; 1976;487. Google Scholar5. QUICKHOPPE CW. Permanent deafness associated with furosemide administration. Ann Otol Rhinol Laryngol. 1975;84:94-101. CrossrefMedlineGoogle Scholar6. SCHWARTZDAVIDRIGGIOSTENZELRUBIN GDRKA. Ototoxicity induced by furosemide. N Engl J Med. 1970;282:1413-4. CrossrefMedlineGoogle Scholar7. AJODHADIX JM. Drug-induced deafness and its treatment. Practitioner. 1976;216:561-70. MedlineGoogle Scholar8. KEEFE P. Ototoxicity from oral furosemide. Drug Intell Clin Pharm. 1978;12:428-9. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: KEVIN L. GALLAGHER, R.PH.; JUDITH K. JONES, M.D., Ph.D.Affiliations: Food and Drug Administration Rockville, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byChoosing the right chronic medication for hemodialysis patients. A short ABC for the dialysis nephrologistVolume Management With Peritoneal DialysisIdentifying targets to prevent aminoglycoside ototoxicityHypertension Associated With Hearing Loss and Tinnitus Among Hypertensive Adults at a Tertiary Hospital in South AfricaDiuretic therapy in congestive heart failureLong-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescueContribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of FurosemideIntravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in miceDifferent infusion durations for preventing platinum-induced hearing loss in children with cancerLoop Diuretic Resistance in a Patient with Acute Heart FailurePredicting the Need for a Tier II Ototoxicity Study From Early Renal Function DataMedical interventions for the prevention of platinum-induced hearing loss in children with cancerCochrane corner: platinum-induced hearing loss after treatment for childhood cancerPlatinum-induced hearing loss after treatment for childhood cancerProlonged furosemide exposure and risk of abnormal newborn hearing screen in premature infantsDifferent infusion durations for preventing platinum-induced hearing loss in children with cancerProspective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing LossDeterminants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects studyOtotoxic effects and mechanisms of loop diureticsMedical interventions for the prevention of platinum-induced hearing loss in children with cancerDifferent infusion durations for preventing platinum-induced hearing loss in children with cancerLoop Diuretics in the Treatment of HypertensionHypertension, Diuretic Use, and Risk of Hearing LossDigoxin, Diuretics, and Vasodilators in Patients with Heart FailureRefractory Edema with Congestive Heart Failure Stepwise Approaches Nephrology PerspectivesMedical interventions for the prevention of platinum-induced hearing loss in children with cancerDifferent infusion durations for preventing platinum-induced hearing loss in children with cancerEffectiveness of Bumetanide Infusion in Treatment of Generalized Edema and Congestive Heart FailureDifferent infusion durations for preventing platinum-induced hearing loss in children with cancerClinical Pharmacology of Furosemide in Neonates: A ReviewPlatinum-induced hearing loss after treatment for childhood cancerMedical interventions for the prevention of platinum-induced hearing loss in children with cancerMedical interventions for the prevention of platinum-induced hearing loss in children with cancerRegulation of Fluids and ElectrolytesRenal PharmacologyVolume Resuscitation and ManagementIndications to Start Kidney Replacement TherapyNitroprusside in decompensated heart failure: What should a clinician really know?Acute Sensorineural Hearing Loss: Furosemide Ototoxicity RevisitedA probable case of gabapentin-related reversible hearing loss in a patient with acute renal failurePredictors of Faster Decline of Residual Renal Function in Taiwanese Peritoneal Dialysis PatientsManaging acute renal failureRenal PharmacologyRegulation of Fluids and Electrolytes in Infants and ChildrenChildhood Vestibular DisordersLoop diuretics: from the Na-K-2Cl transporter to clinical useStrategies for Treatment and Prevention of Acute Renal FailureOtotoxicity Induced by Gentamicin and FurosemideEffect of posture on sodium excretion and diuretic efficacy in nephrotic patientsTreatment of Edematous Disorders with DiureticsTreatment of Edematous Disorders with DiureticsPharmacoeconomic Comparison of an Albumin-Furosemide Complex Versus Sequential Therapy for Renal InsufficiencyDiuretic TherapyMolecular and clinical implications of loop diuretic ototoxicityEffect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failureOtotoxicity: Of Mice and MenContinuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistanceA CLINICAL REVIEW OF OTOTOXICITYDose-response relationships for furosemide ototoxicity in ratOtotoxicity of Loop DiureticsPharmacokinetics of Furosemide in EndolymphDrug Use in the NewbornLoop Diuretics for Chronic Renal Insufficiency: A Continuous Infusion Is More Efficacious Than Bolus TherapyDavid W. Rudy, MD, James R. Voelker, MD, Paula K. Greene, RN, Francisco A. Esparza, MS, D. Craig Brater, MDOtotoxicity: Morphological and Functional Correlations between Experimental and Clinical StudiesDrug-induced ototoxicitySouthwestern Internal Medicine Conference: Drug Therapy in the Management of Acute Renal FailureUntersuchungen zur extrarenalen Wirkung von DiuretikaComparative Ototoxicity of Furosemide and PiretanideFurosemide ototoxicity: Clinical and experimental aspectsPrevention of Acute Renal Failure: 1985Klinische Pharmakologie der antihypertensiven PharmakotherapieEffect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humansEffect of furosemide upon endolymph potassium concentrationClinical Pharmacology of Bleomycin and CisplatinDisorders of body fluids, sodium and potassium in chronic renal failureNutritional Management of Chronic Renal FailureA Survey of the Effects of Loop Diuretics on the Zonulae Occludentes of the Perilymph-Endolymph Barrier by Freeze FractureThe Pharmacology of Ototoxic DrugsClinical pharmacology of bleomycin and cisplatinPharmakokinetik und Pharmakodynamik von Furosemid bei Normalpersonen, Leberzirrhose mit Ascites und terminaler NiereninsuffizienzHörstörungen 1 November 1979Volume 91, Issue 5Page: 744-745KeywordsAdverse reactionsDeafnessDrug administrationDrugsFood and Drug AdministrationRenal failure ePublished: 1 December 2008 Issue Published: 1 November 1979 PDF downloadLoading ...